Massachusetts University First to Pilot NALCAM, a New Technology Advancing Naloxone Carriage and Overdose Prevention

13.05.25 15:23 Uhr

BOSTON, May 13, 2025 /PRNewswire/ -- Q2i, a leader in digital health innovation, has launched NALCAM, a pioneering technology designed to increase the carriage of Naloxone—a life-saving medication used to reverse opioid overdoses. This initiative aims to improve access and consistent carrying of Naloxone, helping individuals respond more effectively in critical overdose situations.

NALCAM

Developed by Q2i's contingency management division, NALCAM uses motivational incentives to encourage individuals to carry Naloxone regularly. The program helps bridge the gap between Naloxone distribution and real-world usage, supporting rapid intervention when it matters most.

Worcester Polytechnic Institute (WPI) was the first institution to participate in the NALCAM pilot, providing an opportunity to explore how higher education settings can support community-focused public health strategies.

Q2i CEO Steve Jenkins stated, "We designed NALCAM to support people in making potentially life-saving choices. By combining behavioral science with public health tools, this technology empowers individuals and organizations to prioritize safety through regular Naloxone carriage."

Dr. Matilde Castiel, Commissioner of Health and Human Services for Worcester, emphasized the broader significance of the program: "Worcester is home to many colleges and universities, and initiatives like NALCAM show how higher education can proactively address public health challenges. This program encourages immediate responses to overdose emergencies and has the potential to save lives, setting a new standard for public health interventions."

Key Benefits of NALCAM Include:

Harm Reduction: Empowers bystanders to respond effectively to overdoses.

Stigma Reduction: Supports open, informed conversations around addiction and recovery.

Community Impact: Builds awareness and preparedness at the individual and institutional levels.

As the opioid crisis continues to affect communities nationwide, NALCAM represents a forward-thinking approach to harm reduction. Q2i welcomes collaboration with campuses, health systems, and community partners seeking to enhance overdose prevention efforts.

For more information or partnership inquiries, visit Q2i.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/massachusetts-university-first-to-pilot-nalcam-a-new-technology-advancing-naloxone-carriage-and-overdose-prevention-302453641.html

SOURCE Q2i